DETREND PRICE OSCILLATOR
Trading: SELL @ $185.35
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
CSL (ASX:CSL) currently has a confirmed downtrend. Price is currently below the displaced moving average for CSL Currently, the return on DPO20 is 0.7%.
The Detrended Price Oscillator (DPO) is an indicator designed to remove trend from price and make it easier to identify cycles. DPO does not extend to the last date because it is based on a displaced moving average. However alignment with the most recent is not an issue because DPO is not a momentum oscillator. Instead DPO is used to identify cycle’s highs/lows and estimate cycle length.
Calculation: Detrended Price Oscillator (DPO):
1) Price (X/2 + 1) periods ago minus X-period simple moving average.
Where X is the number of periods;
PROFILE: CSL (CSL.AX)
Stock Exchange: ASX
Ticker Codes: | CSL.AX | ASX:CSL |
CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, and internationally. It operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of bleeding disorders, including hemophilia and von Willebrand disease, primary and secondary immunodeficiency's, hereditary angioedema, neurological disorders, and inherited respiratory diseases. Its products are also used to prevent haemolytic diseases in newborns and infections in solid organ transplant recipients, as well as specific infections; and for urgent warfarin reversal in patients with acute major bleeding, as well as victims of trauma, shocks, and burns. In addition, this segment operates approximately 180 human blood plasma collection centers. Further, it conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and offers influenza vaccines. It also provides in-licensed vaccines and specialty pharmaceuticals; manufactures and markets diagnostics for immunohematology laboratories; and supplies a range of products, including antivenoms and Q fever vaccines. The company was founded in 1916 and is headquartered in Parkville, Australia.
Detrended Price OscillatorDownload
|GCY Gascoyne Resources||0.11||11.1||1,637,598||-0.03||BEARISH|
|OGC Oceanagold Corporation||4.73||6.3||557,211||-0.11||BEARISH|
|AYS Amaysim Australia||0.95||5.6||94,182||-0.03||BEARISH|
|CLQ Clean Teq Holdings||0.33||4.8||1,404,811||-0.11||BEARISH|
|OSP Osprey Medical||0.11||4.8||5,000||-0.01||BEARISH|
|SAR Saracen Mineral||3.05||4.8||5,818,759||0||BEARISH|